Name:
Dr Phil Jeffrey
Organisation:
Bicycle Therapeutics
Year elected:
2021
Primary professional setting:
Industry
Phil Jeffrey is Senior Vice President of Preclinical Development at Bicycle Therapeutics and has over 35 years’ experience in the pharmaceutical industry. He has a successful track record in drug discovery from early lead optimisation through to clinical proof of mechanism and proof of concept, across a wide variety of therapeutic areas and drug modalities. Phil previously held positions at Pfizer, GlaxoSmithKline, SmithKline Beecham and The Upjohn Company. He holds a PhD in Drug Metabolism and Pharmacokinetics from the University of Sheffield, is an Honorary Professor at the William Harvey Research Institute, Queen Mary University of London, is an editor for the British Journal of Pharmacology and a member of the editorial board for Xenobiotica.